Skip to main content
main-content

Asthma

Asthma

07-02-2019 | Asthma | News | Article

No benefit of antibiotic treatment for hospitalised asthma patients

Findings from a large US study suggest that early treatment with antibiotics is not associated with improved outcomes among patients hospitalised for asthma exacerbation and treated with systemic corticosteroids.

17-01-2019 | Asthma | News | Article

Better adherence with once- than twice-daily ICS/LABA therapy in asthma patients

Patients with asthma who are treated with the once-daily inhaled corticosteroid/long-acting beta agonist regimen fluticasone furoate/vilanterol have better treatment adherence than those taking the twice-daily budesonide/formoterol combination, researchers report.

14-01-2019 | Asthma | News | Article

Most patients with asthma will not experience an exacerbation

Only a third of patients with asthma will experience an exacerbation, show 7 years of observation in more than 50,000 adults with the condition.

20-12-2018 | Asthma | News | Article

Genetic variants linked to moderate-to-severe asthma susceptibility

A genome-wide association study has identified novel genetic variants associated with the risk of developing moderate-to-severe asthma, a substantial proportion of which are also associated with mild asthma susceptibility.

18-12-2018 | Asthma | News | Article

Blood eosinophil variability has treatment decision effects

Researchers have highlighted the need for blood eosinophils to be repeatedly measured in patients with severe asthma when designating treatment having found that levels vary in individuals over time.

06-12-2018 | Asthma | News | Article

Tralokinumab does not reduce corticosteroid use in patients with severe asthma

Findings from the TROPOS trial indicate that treatment with the interleukin-13-targeted monoclonal antibody tralokinumab does not decrease corticosteroid use among patients with severe uncontrolled asthma.

01-11-2018 | Asthma | News | Article

COLUMBA results support long-term use of mepolizumab in patients with severe asthma

The anti-interleukin-5 monoclonal antibody mepolizumab has durable safety and efficacy profiles over an average 3.5 years of follow-up in patients with severe eosinophilic asthma, indicate findings from the COLUMBA open-label extension study.

11-10-2018 | Asthma | News | Article

Changing inhaler device does not compromise asthma treatment effectiveness

Results of a real-world study suggest that changing from a dry powder inhaler to a pressurized metered-dose inhaler is not associated with compromised treatment outcomes among patients with asthma.

03-10-2018 | Asthma | News | Article

Systemic corticosteroids reduce blood eosinophil counts

Systemic corticosteroid treatment reduces blood eosinophil counts and low levels are maintained for weeks after treatment is discontinued, show real-world data.

06-09-2018 | Asthma | News | Article

Single blood eosinophil measure predicts eosinophilic asthma

A single blood eosinophil count could predict persistent eosinophilia in patients with adult-onset asthma, study findings show.

03-09-2018 | Asthma | News | Article

Proportion of asthma patients who could benefit from anti-IL-5 treatment estimated

Researchers estimate that 2% of patients with adult-onset eosinophilic asthma could benefit from treatment involving antibodies against the interleukin-5 pathway.

24-07-2018 | Asthma | News | Article

Proportion of asthma patients who could benefit from anti-IL-5 treatment estimated

Researchers estimate that 2% of patients with adult-onset eosinophilic asthma could benefit from treatment involving antibodies against the interleukin-5 pathway.

04-07-2018 | Asthma | News | Article

Asthma risk prediction score accounts for early treatment response

Researchers have developed a measure for predicting future asthma risk based on patient characteristics and current level of asthma control.

20-06-2018 | Asthma | News | Article

Good prognosis for patients with mild asthma

Research findings can reassure patients with mild asthma that the long-term prognosis is good, with only a tenth of patients transitioning to more severe disease over 10 years.

08-05-2018 | Asthma | News | Article

Eosinophilia linked to lung function decline irrespective of asthma symptoms

High blood eosinophil counts are associated with airflow obstruction and lung function decline in patients with asthma, but also in people without respiratory symptoms, population-based study findings show.

12-03-2018 | Asthma | News | Article

Exacerbation frequency linked to lung function decline in severe eosinophilic asthma

Repeated exacerbations in patients with severe eosinophilic asthma may be associated with accelerated deterioration of lung function, study findings show.

13-02-2018 | Asthma | News | Article

Initiation criteria for mepolizumab sufficient for determining long-term benefit

Researchers have been unable to find a reliable rule for identifying patients who are likely to benefit from continued long-term mepolizumab treatment for severe eosinophilic asthma.

16-01-2018 | Asthma | News | Article

Allergic airway inflammation stimulates a dynamic ILC2 phenotype

Researchers have found that the group 2 innate lymphoid cell phenotype is more heterogeneous than previously thought, with a surface marker and gene expression profile that is highly dynamic.

18-12-2017 | Asthma | News | Article

Increasing physical activity could aid severe asthma management

Researchers recommend addressing inactivity and sedentary time as a possible nonpharmacologic approach to managing severe asthma.

04-10-2017 | Asthma | News | Article

B cells have key role in Th-mediated allergic response

Results of a study conducted in mouse models of allergy suggest that B cells have an important role in propagating T-helper cell-mediated responses to house dust mites.

image credits